Medicare Enrolled
Dr. Thomas Lomis, M.D.
Surgical Oncology Physician · Van Nuys, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lomis from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lomis?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lomis
Dr. Thomas Lomis is a surgical oncology physician in Van Nuys, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Lomis performed 1,158 Medicare services across 987 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lomis received a total of $5,280 from 63 pharmaceutical and/or device companies across 211 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in surgical oncology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lomis is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 9% volume in CA
$5,280 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,158
Medicare services
Top 9% in CA for surgical oncology physician
987
Unique beneficiaries
$156
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~61 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
240 | $103 | $274 |
| Screening mammography An X-ray of the breast used to detect breast cancer in women who have no signs or symptoms of the disease. |
117 | $147 | $475 |
| 3D screening mammography (tomosynthesis) A screening imaging test of the breast using 3D technology to detect potential abnormalities. |
114 | $59 | $285 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
91 | $66 | $150 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
81 | $130 | $374 |
| Complete breast ultrasound, 1 breast A complete ultrasound examination of one breast to visualize internal structures. |
78 | $122 | $349 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
76 | $75 | $185 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
68 | $145 | $400 |
| Digital breast tomosynthesis (3D mammogram) A specialized imaging test that creates three-dimensional pictures of the breast tissue to help detect abnormalities. |
53 | $43 | $290 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 42 | $281 | $1,500 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
39 | $1,479 | $9,800 |
| Diagnostic mammography of both breasts | 36 | $128 | $600 |
| Diagnostic mammography of 1 breast An X-ray examination of one breast to evaluate specific breast symptoms or abnormalities. |
33 | $102 | $465 |
| Online digital E/M service, established patient, 11-20 min An online digital evaluation and management service for an established patient. The service involves a total time of 11 to 20 minutes over a period of up to 7 days. |
27 | $25 | $265 |
| Limited ultrasound of 1 breast A focused ultrasound examination of a single breast to evaluate specific areas of concern. |
18 | $77 | $189 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
17 | $291 | $1,025 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
15 | $100 | $786 |
| CT scan of abdomen and pelvis, without contrast A computed tomography scan that creates detailed images of the abdominal and pelvic organs. The procedure is performed without the use of intravenous contrast dye. |
13 | $152 | $980 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$5,280
Total received (2018-2024)
Avg $754/year across 7 years
Top 26% in CA for surgical oncology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
63
Companies
211
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,280 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$803
2023
$556
2022
$718
2021
$925
2020
$274
2019
$778
2018
$1,226
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PROGENICS PHARMACEUTICALS, INC.
$125
Philips North America LLC
$103
Novartis Pharmaceuticals Corporation
$82
PUMA BIOTECHNOLOGY, INC.
$53
Regeneron Healthcare Solutions, Inc.
$38
Karyopharm Therapeutics Inc.
$35
Gilead Sciences, Inc.
$34
PFIZER INC.
$33
Lilly USA, LLC
$30
Daiichi Sankyo Inc.
$30
Blue Earth Diagnostics Limited
$27
JAZZ PHARMACEUTICALS INC.
$27
Ipsen Biopharmaceuticals, Inc
$27
Eisai Inc.
$25
Tempus AI, Inc
$25
AstraZeneca Pharmaceuticals LP
$24
SUN PHARMACEUTICAL INDUSTRIES INC.
$24
Merck Sharp & Dohme LLC
$22
PharmaEssentia USA Corporation
$22
Fennec Pharmaceuticals, Inc.
$19
Top 3 companies account for 38.6% of 2024 payments
All-time payments by company (2018-2024) ›
Ipsen Biopharmaceuticals, Inc
$518
AstraZeneca Pharmaceuticals LP
$369
Novartis Pharmaceuticals Corporation
$245
Genentech USA, Inc.
$234
Intuitive Surgical, Inc.
$229
Karyopharm Therapeutics Inc.
$198
Bayer HealthCare Pharmaceuticals Inc.
$190
Amgen Inc.
$176
TESARO, Inc.
$151
Merck Sharp & Dohme LLC
$142
Alexion Pharmaceuticals, Inc.
$141
Boehringer Ingelheim Pharmaceuticals, Inc.
$139
Regeneron Healthcare Solutions, Inc.
$138
PROGENICS PHARMACEUTICALS, INC.
$125
Incyte Corporation
$124
PUMA BIOTECHNOLOGY, INC.
$108
Lilly USA, LLC
$107
GlaxoSmithKline, LLC.
$106
Philips North America LLC
$103
Teva Pharmaceuticals USA, Inc.
$101
Takeda Pharmaceuticals U.S.A., Inc.
$98
Daiichi Sankyo Inc.
$93
GENZYME CORPORATION
$76
Exelixis Inc.
$74
Taiho Oncology, Inc.
$72
LEICA MICROSYSTEMS INC.
$68
Blueprint Medicines Corporation
$65
Seattle Genetics, Inc.
$62
TerSera Therapeutics LLC
$57
Seagen Inc.
$50
PFIZER INC.
$47
JAZZ PHARMACEUTICALS INC.
$47
Mallinckrodt LLC
$47
Eisai Inc.
$45
Ethicon US, LLC
$41
Kyowa Kirin, Inc.
$40
EISAI INC.
$39
Covidien LP
$37
Baxter Healthcare
$35
Janssen Biotech, Inc.
$35
Puma Biotechnology, Inc.
$35
Gilead Sciences, Inc.
$34
Coherus Biosciences Inc.
$29
Heron Therapeutics, Inc.
$28
Blue Earth Diagnostics Limited
$27
GE HEALTHCARE
$25
Tempus AI, Inc
$25
SUN PHARMACEUTICAL INDUSTRIES INC.
$24
Curium US LLC
$23
Stemline Therapeutics Inc.
$23
PharmaEssentia USA Corporation
$22
CTI BioPharma Corp.
$22
Agios Pharmaceuticals, Inc.
$21
E.R. Squibb & Sons, L.L.C.
$21
G1 Therapeutics, Inc.
$19
Fennec Pharmaceuticals, Inc.
$19
Epizyme, Inc.,
$18
TOLMAR Pharmaceuticals, Inc.
$18
Bayer Healthcare Pharmaceuticals Inc.
$17
Aveo Pharmaceuticals, Inc.
$16
TELA Bio, Inc.
$16
MorphoSys, US Inc.
$16
Novocure Inc.
$13
Top 3 companies account for 21.4% of all-time payments
Associated products mentioned in payments ›
(AP1) Zenition 70 · ADCETRIS · AFINITOR · AYVAKIT · BENDEKA · BESREMI · CABLIVI · CINVANTI · COSELA · CYRAMZA · Cabometyx · Da Vinci Surgical System · Detectnet · ELIGARD · ENHERTU · ERBITUX · Echelon Flex · Enhertu · FASLODEX · FOTIVDA · FRUZAQLA · GAVRETO · GILOTRIF · HydroMARK Breast Biopsy Site Marker · IMFINZI · INJECTAFER · JAKAFI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · LigaSure · Lonsurf · MAMMOTOME · MEKINIST · MONJUVI · NERLYNX · NINLARO · Nerlynx · Neuwave · Nplate · Nubeqa · OFIRMEV · OPDIVO · Oncology · Onivyde · Orserdu · Ovitex · PADCEV · POSLUMA · POTELIGEO · PROMACTA · PYLARIFY · Pedmark · Perjeta · Phesgo · SANCUSO · SANDOSTATIN · SOLIRIS · SOMATULINE DEPOT · Somatuline Depot · Stivarga · Sustol · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · TISSEEL · TIVDAK · ULTOMIRIS · Udenyca · Ultomiris · VERZENIO · Vitrakvi · Vonjo · XALKORI · XPOVIO · YONSA · ZEJULA · ZEPZELCA · ZOLADEX · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Surgical oncology physicians within 10 mi
71
Per 100K population
0.7
County median income
$87,760
Nearest hospital
VALLEY PRESBYTERIAN HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lomis is a clinical cardiology specialist, with above-average Medicare volume (top 9% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lomis experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Lomis performed 240 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lomis receive payments from pharmaceutical companies?
Yes. Dr. Lomis received a total of $5,280 from 63 companies across 211 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lomis's costs compare to other surgical oncology physicians in Van Nuys?
Dr. Lomis's average Medicare payment per service is $156. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lomis) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Surgical Oncology Physicians in Van Nuys
Browse surgical oncology physicians in Van Nuys ranked by procedure volume and transparency data.
Highest volume
Top Surgical Oncology Physicians in CA
Surgical oncology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Surgical Oncology Physicians in CA
Which CA surgical oncology physicians receive the most from drug and device companies.
By company
Ipsen Biopharmaceuticals, Inc Payments to Doctors
See all physicians who received payments from Ipsen Biopharmaceuticals, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology